CD24 Expression is Specific for Tamoxifen-resistant Ductal Breast Cancer Cases

Background: In breast cancer, the expression of CD24 represents a poorly recognised unfavourable prognostic factor. CD24 has been described to be potentially down-regulated by estrogen receptor alpha (ER). The present study was aimed at examining the predictive value of CD24 expression in tamoxifen-...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-01, Vol.26 (1B), p.629-634
Main Authors: SUROWIAK, Pawel, MATERNA, Verena, LAGE, Hermann, ZABEL, Maciej, PALUCHOWSKI, Piotr, MATKOWSKI, Rafal, WOJNAR, Andrzej, MACIEJCZYK, Adam, PUDELKO, Marek, KORNAFEL, Jan, DIETEL, Manfred, KRISTIANSEN, Glen
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Hormonal - pharmacology
Biological and medical sciences
Biomarkers, Tumor - biosynthesis
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Carcinoma, Ductal, Breast - drug therapy
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - pathology
CD24 Antigen - biosynthesis
Drug Resistance, Neoplasm
Female
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry
Mammary gland diseases
Medical sciences
Middle Aged
Predictive Value of Tests
Receptors, Estrogen - biosynthesis
Tamoxifen - pharmacology
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In breast cancer, the expression of CD24 represents a poorly recognised unfavourable prognostic factor. CD24 has been described to be potentially down-regulated by estrogen receptor alpha (ER). The present study was aimed at examining the predictive value of CD24 expression in tamoxifen-treated breast cancer cases. Materials and Methods: Sixty patients with primary invasive ductal breast cancers with post-operative tamoxifen treatment were enrolled in the study. Immmunohistochemical reactions were performed using monoclonal antibodies directed against CD24 and ER. Results: Cases demonstrating cytoplasmic-membranous expression of CD24 (CD24c-m) proved to be characterised by a significantly lower expression of ER as compared to CD24c-m-negative cases. A multivariate progression analysis based on the Cox proportional hazard model demonstrated that CD24c-m expression is an independent prognostic factor for poor overall survival. Conclusion: The data from the present study suggested that CD24c-m expression is specific for tamoxifen-resistant breast cancer cases. CD24 should be subjected to comprehensive studies as a marker of resistance to tamoxifen treatment.
ISSN:0250-7005
1791-7530